Algernon Pharmaceuticals Confirms DMT Increased Growth of Neurons by 40% in Preclinical Study at Sub Hallucinogenic Dose
September 07, 2021 07:30 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage...
Algernon Pharmaceuticals Announces Small Cell Lung Cancer Ifenprodil Research Program and Appoints Dr. William North as Lead Consultant
August 11, 2021 07:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
Algernon Pharmaceuticals Announces Exclusive Licensing Agreement with Dartmouth College
August 09, 2021 07:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
Algernon Pharmaceuticals Provides Year End Summary of Key Activities
December 30, 2020 08:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
Algernon Pharmaceuticals Announces OTC Trading Symbol Change to AGNPF
December 30, 2019 06:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Dec. 30, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
Algernon Pharmaceuticals Appoints Leading Respirologist Dr. Martin Kolb to Its Medical and Scientific Advisory Board
December 16, 2019 06:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Company” or “Algernon”), a clinical stage pharmaceutical...
Algernon Pharmaceuticals Selects NP-120 (Ifenprodil) for its Lead Phase 2 Trial for Idiopathic Pulmonary Fibrosis and Chronic Cough
December 09, 2019 06:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Company” or “Algernon”), a clinical stage pharmaceutical...
Algernon Pharmaceuticals Provides Update on its Planned Phase II Clinical Trial
November 25, 2019 07:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, B.C., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development...
Algernon Announces Closing of $2.07 Million Prospectus Offering of Units
November 01, 2019 09:31 ET
|
Algernon Pharmaceuticals
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc....
Algernon Announces Pricing of Prospectus Offering
September 06, 2019 07:00 ET
|
Algernon Pharmaceuticals
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Sept. 06, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc....